August 4, 2022
Eli Lilly Japan and Sumitomo Pharma said on August 3 that their marketing collaboration for the type 2 diabetes drug Trulicity (dulaglutide) will conclude upon the expiration of their agreement on December 31. While Lilly holds the marketing authorization for...read more